New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections

Current Opinion in Pharmacology

Volumn 4, Issue 5, 2004, Pages 431-436

  Otto, Michael J ^a  

^a PHARMASSET INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXY 3' OXA 4' THIOCYTIDINE; 3' FLUOROTHYMIDINE; ABACAVIR; AMDOXOVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; ELVUCITABINE; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; NEW DRUG; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; SPD 754; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE; 1,3 DIOXOLANE DERIVATIVE; 2' DEOXY 3' OXA THIOCYTIDINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 2',3'-DIDEOXY-5-FLUORO-3'-THIACYTIDINE; 2'-DEOXY-3'-OXA-THIOCYTIDINE; 2,6 DIAMINOPURINE DIOXOLANE; 2,6-DIAMINOPURINE DIOXOLANE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYTIDINE TRIPHOSPHATE; DEOXYCYTIDINE; DEXELVUCITABINE; DRUG DERIVATIVE; NUCLEOSIDE; PURINE NUCLEOSIDE; ZALCITABINE;

ANTIVIRAL ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG DESIGN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; LIVER TOXICITY; PRIORITY JOURNAL; STRUCTURE ANALYSIS; TREATMENT FAILURE; ANIMAL; REVIEW;

ANIMALS; ANTI-HIV AGENTS; CLINICAL TRIALS; CYTIDINE TRIPHOSPHATE; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DIOXOLANES; HIV INFECTIONS; HUMANS; PURINE NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS; THIONUCLEOSIDES; ZALCITABINE;

EID: 16644398251     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2004.06.001     Document Type: Review

References (47)

1. A. Cossarizza G. Moyle Antiretroviral nucleoside and nucleotide analogues and mitochondria AIDS 18 2004 137-151
2. R. Fleischer D. Boxwell K.E. Sherman Nucleoside analogues and mitochondrial toxicity Clin Infect Dis 38 2004 e79-80
3. A. Macher D. Thomas S.M. Paul Contraindicated antiretroviral drug combinations N J Med 100 2003 41-43
4. P. Pecora Fulco M.A. Kirian Effect of tenofovir on didanosine absorption in patients with HIV Ann Pharmacother 37 2003 1325-1328
5. J.E. Gallant P.Z. Gerondelis M.A. Wainberg N.S. Shulman R.H. Haubrich M. St. Clair E.R. Lanier N.S. Hellmann D.D. Richman Nucleoside and nucleotide analgue reverse transcriptase inhibitors: A clinical review of antiretroviral resistance Antivir Ther 8 2003 489-506
6. A.G. Marcelin C. Delaugerre M. Wirden P. Viegas A. Simon C. Katlama V. Calvez Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure J Med Virol 72 2004 162-165
7. E. De Clercq Antiviral drugs in current clinical use J Clin Virol 30 2004 115-133
8. P.L. Sharma V. Nurpeisov B. Hernandez-Santiago T. Beltran R.F. Schinazi Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase Curr Top Med Chem 4 2004 895-919
9. L.M. Bang L.J. Scott Emtricitabine: An antiretroviral agent for HIV infection Drugs 63 2003 2413-2424
10. Van der Horst C, Sanne I, Wakeford C, Quinn J, Rousseau F: Two randomized, controlled, equivalence trials of emtricitabine to lamivudine. 8th Conference on Retroviruses and Opportunistic Infections, February 4-8 2001, Chicago, Illinois [Abstract 18].
11. J.M. Molina G. Peytavin S. Perusat C. Lascoux-Combes D. Sereni W. Rozenbaum G. Chene Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial) HIV Med 5 2004 99-104
12. F.S. Rousseau J.O. Kahn M. Thompson D. Mildvan D. Shepp J.P. Sommadossi J. Delehanty J.N. Simpson L.H. Wang J.B. Quinn et al. Prototype trial design for rapid dose selection of antiretroviral drugs: An example using emtricitabine (Coviracil) J Antimicrob Chemother 48 2001 507-513
13. F.S. Rousseau C. Wakeford H. Mommeja-Marin I. Sanne C. Moxham J. Harris L. Hulett L.H. Wang J.B. Quinn D.W. Barry FTC-102 Clinical Trial Group. Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients J Infect Dis 188 2003 1652-1658
14. P. Cahn Emtricitabine: A new nucleoside analogue for once-daily antiretroviral therapy Expert Opin Investig Drugs 13 2004 55-68
15. J.M. Molina F. Ferchal C. Rancinan F. Raffi W. Rozenbaum D. Sereni P. Morlat V. Journot J.M. Decazes G. Chene Once-daily combination of emtricitabine, didanosine and efavirenz in human immunodeficiency virus-infected patients J Infect Dis 182 2000 599-602
16. Saag M, Cahn P, Raffi F, Wolf M, Rousseau FS, Pearce D, Molina JM, Shaw AL, Borroto-Esoda KE, Hinkle JE et al.: A randomized, double-blind, multicenter comparison of emtricitabine QD to stavudine BID. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 26-30 2002, San Diego, California [Abstract LB1].
17. Cahn P, Raffi F, Saag M, Wolf M, Pearce D, Molina JM, Borroto-Esoda KE, Shaw AL, Hinkle JE, Waters JM et al.: Virologic efficacy and patterns of resistance mutations in ART-naïve patients receiving combination therapy with once-daily emtricitabine compared to twice-daily stavudine in a randomized, double-blind, multicenter clinical trial. 10th Conference on Retroviruses and Opportunistic Infections, February 10-14 2003, Boston, Massachusetts [Abstract 606].
18. R.F. Schinazi R.M. Lloyd Jr. M.H. Nguyen D.L. Cannon A. McMillan N. Ilksoy C.K. Chu D.C. Liotta H.Z. Bazmi J.W. Mellors Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides Antimicrob Agents Chemother 37 1993 875-881
19. R.F. Schinazi Assessment of the relative potency of emtricitabine and lamivudine J Acquir Immune Defic Syndr 34 2003 243-245
20. T. Chapman J. McGraw S. Noble Tenofovir disoproxil fumarate Drugs 63 2003 1597-1608
21. E.Y. Kim L. Vrang B. Oberg T.C. Merigan Anti-HIV type 1 activity of 3′-fluoro-3′-deoxythymidine for several different multidrug-resistant mutants AIDS Res Hum Retroviruses 17 2001 401-407
22. S. Rusconi Alovudine Medivir Curr Opin Investig Drugs 4 2003 219-223
23. C. Flexner C. van der Horst M.A. Jacobson W. Powderly F. Duncanson D. Ganes P.A. Barditch-Crovo B.G. Petty P.A. Baron D. Armstrong et al. Relationship between plasma concentrations of 3′-deoxy-3′-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials J Infect Dis 170 1994 1394-1403
24. V. Calvez R. Tubiana J. Ghosn M. Wirden A.G. Marcelin C. Westling H. Shoenz J. Harmenberg G. Mardhs B. Oberg et al. MIV-310 reduces markedly viral load in patients with virological failure despite multiple-drug therapy: Results from a 4 week phase II study Antivir Ther 7 2002 S4
25. H.Z. Bazmi J.L. Hammond S.C. Cavalcanti C.K. Chu R.F. Schinazi J.W. Mellors In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3′-azido-3′-deoxythymidine Antimicrob Agents Chemother 44 2000 1783-1788
26. Z. Gu M.A. Wainberg N. Nguyen-Ba L. L'Heureux J.M. de Muys T.L. Bowlin R.F. Rando Mechanism of action and in vitro activity of 1′,3′-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants Antimicrob Agents Chemother 43 1999 2376-2382
27. Y. Chong K. Borroto-Esoda P.A. Furman R.F. Schinazi C.K. Chu Molecular mechanism of DAPD/DXG against zidovudine- and lamivudine- drug resistant mutants: A molecular modeling approach Antivir Chem Chemother 13 2002 115-128
28. J.P. Mewshaw F.T. Myrick D.A. Wakefield B.J. Hooper J.L. Harris B. McCreedy K. Borroto-Esoda Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails J Acquir Immune Defic Syndr 29 2002 11-20
29. J.L. Jeffrey J.Y. Feng C.C. Qi K.S. Anderson P.A. Furman Dioxolane guanosine 5′triphosphate, an alternative substrate inhibitor of wild-type and mutant HIA-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses J Biol Chem 278 2003 18971-18979
30. th Conference on Retroviruses and Opportunistic Infections, February 10-14 2003, Boston, MA [Abstract 554].
31. R.F. Schinazi A. McMillan D. Cannon R. Mathis R.M. Lloyd A. Peck J.P. Sommadossi M. St. Clair J. Wilson P.A. Furman et al. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine Antimicrob Agents Chemother 36 1992 2423-2431
32. Black PL, Ussery MA, Otto MJ, Stuyver L, Hurwitz SJ, Barnett TM, Mowrey JO, Tharnish PM, Boudinot FD, Schinazi RF: Potent antiviral activity of Racivir in the HuPBMC-SCID mouse model of HIV infection. Frontiers in Drug Development for Antiretroviral Therapies, HIV DART, Dec 17-21 2000, San Juan, Puerto Rico [Abstract 017].
33. Otto MJ, Arastèh K, Schulbin H, Beard A, Cartee L, Liotta DC, Schinazi RF, Murphy RL: Single and multiple dose pharmacokinetics and safety of the nucleoside Racivir in male volunteers. Frontiers in Drug Development for Antiretroviral Therapies, HIV DART, Dec 15-19 2002. Naples, FL [Abstract 044].
34. Otto MJ, Arastèh K, Kreckel P, Drauz D, Beard A, Cartee L, Hurwitz SJ, Liotta DC, Schinazi RF, Murphy RL: Sustained anti-HIV-1 effect of Racivir combined with D4T and Sustiva following a 14-day treatment of infected volunteers. 10th Conference on Retroviruses and Opportunistic Infections, Feb 10-14 2003, Boston, MA [Abstract 552]
35. R.F. Schinazi J.W. Mellors H.Z. Bazmi S. Diamond S. Garber K. Gallagher R. Geleziunas R. Klabe M. Pierce M. Rayner et al. DPC 817: A cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants Antimicrob Agents Chemother 46 2002 1394-1401
36. R. Geleziunas K. Gallagher H. Zhang L. Bacheler S. Garber J.-T. Wu G. Shi M.J. Otto R.F. Schinazi S. Erickson-Viitanen HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor, β-D-2′,3′-dideoxy-2′, 3′-didehydro-5-fluorocytidine Antivir Chem Chemother 14 2003 49-59
37. S. Erickson-Viitanen J.-T. Wu G. Shi S. Unger R.W. King B. Fish R. Klabe R. Geleziunas K. Gallagher M.J. Otto et al. Cellular pharmacology of D-D4FC, a nucleoside analog active against drug-resistant HIV Antivir Chem Chemother 14 2003 39-47
38. R.L. Murphy D. Schurmann I. Kravec A. Beard J. Eron L. Cartee S.J. Hurwitz Erickson-Viitanen D.C. Liotta R.F. Schinazi et al. Pharmacokinetics, safety and antiviral activity of the nucleoside Reverset following single doses in HIV-1 infected patients Antiviral Therapy 8 2003 S330
39. Stuyver LJ, McBrayer TR, Schürmann D, Kravec I, Beard A, Cartee L, Schinazi RF, De La Rosa A, Murphy RL, Otto MJ: Potent antiviral effect of Reverset™ in HIV-1 infected adults following a single oral dose. Antiviral Therapy 2004, in press.
40. J.M. De Muys H. Gourdeau N. Nguyen-Ba D.L. Taylor P.S. Ahmed T. Mansour C. Locas N. Richard M.A. Wainberg R.F. Rando Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2′-deoxy-3′-oxa-4′-thiocytidine Antimicrob Agents Chemother 43 1999 1835-1844
41. N. Richard H. Salomon M. Oliviera R. Rando T. Mansour Z. Gu M.A. Wainberg Selection of resistance-conferring mutations in HIV-1 by the nucleoside reverse transcriptase inhibitors (+/-)dOTC and (+/-)dOTFC Antivir Chem Chemother 11 2000 359-365
42. Francis RJ, Lanclos L, Shiveley L, Sawyer J: Pharmacokinetics of SPD754, a new cytidine analogue in healthy volunteers. Second International AIDS Society Conference on HIV Pathogenesis and Treatment, 2003, Paris [Abstract 528].
43. Cahn P, Lange J, Cassetti I, Sawyer J, Zala C, Rolon M, Bolgna R, Shiveley L: Anti HIV-1 activity of SPD 754, a new NRTI: Results of a 10 day monotherapy study in treatment naïve HIV patients. 2nd IAS Conference on HIV Pathogenesis and Treatment, July 13-16 2003, Paris, France [Abstract LB15].
44. Collins P, Shiveley L, Anderson C, Bethell R: Analysis of the genotypes of viruses isolated from patients after 10 days monotherapy with SPD754. 11th Conference on Retroviruses and Opportunistic Infection, February 8-11 2004, San Francisco, CA [Abstract 526].
45. Bethell R, Adams J, De Muys J, Lippens J, Richard A, Hamelin B, Ren C, Collins P, Struthers-Semple C, Holdich T, Sawyer J: Pharmacological evaluation of a dual deoxycytidine analogue combination: 3TC and SPD754. 11th Conference on Retroviruses and Opportunistic Infections, February 8-11 2004, San Francisco, CA [Abstract 138].
46. Dunkle LM, Oshana S, Dickson J, Cheng Y, Rice WG: Phase I safety and pharmacokinetics of ACH-126 443, a potent anti-HIV and HBV nucleoside. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, September 22-25 2001, Chicago, IL [Abstract A-508].
47. L.M. Dunkle J.C. Gathe D.E. Pedevillano H.G. Robison W.G. Rice J.C. Pottage Jr. the ACH-006 Study Team Elvucitabine: Potent antiviral activity demonstrated in multi-drug resistant HIV infection Antivir Ther 8 2003 S5